Oxycodone is under clinical development by MEDRx and currently in Phase I for Pain. According to GlobalData, Phase I drugs for Pain have a 75% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Oxycodone’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Oxycodone overview

Oxycodone (MRX-1OXT) is under development for the treatment of moderate to severe pain. The therapeutic candidate is administered  transdermally in the form of patch. Oxycodone is a semisynthetic opiate agonist derived from the opioid alkaloid that targets mu receptor. It acts as a narcotic analgesic. The development of the drug candidate is based on the Ionic liquid transdermal system (ILTS) technology.

MEDRx overview

MEDRx through its subsidiaries carries out development of pharmaceutical drug based on the transdermal absorption system. The company focuses on ionic liquid technology to develop ionic liquid transdermal system (ILTS) and transdermal medicines that include ETOREAT, MRX-10XT, MRX-5LBT, MRX-4TZT and MRX-5DML. The company also develops anti-Alzheimer’s drugs, local analgesics and antidepressants. MEDRx also offers microneedle array “Patch Vaccine” for providing vaccines. It partners with many pharmaceutical companies for development of various drugs. The company operates across the US and Japan. MEDRx is headquartered in Higashikagawa City, Japan.

For a complete picture of Oxycodone’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 20 May 2024

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.